<DOC>
	<DOCNO>NCT00112047</DOCNO>
	<brief_summary>The purpose Study GS-01-934 ass efficacy safety two simplified antiretroviral treatment ( ART ) regimens ART-naive , human immunodeficiency virus , type 1 ( HIV-1 ) infect participant . The primary objective study assess noninferiority emtricitabine ( FTC ) tenofovir disoproxil fumarate ( tenofovir DF ; TDF ) combination efavirenz ( EFV ) relative Combivir ( CBV ) combination EFV treatment HIV-1 infect ART-naive participant , determine achievement maintenance confirm HIV-1 ribonucleic acid ( RNA ) &lt; 400 copies/mL ( c/mL ) Week 48 , define United States ( US ) Food Drug Administration ( FDA ) time-to-loss-of-virologic-response ( TLOVR ) algorithm .</brief_summary>
	<brief_title>Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz Antiretroviral-Naive HIV-1 Infected Subjects</brief_title>
	<detailed_description>This study originally plan 48-week , Phase 3 , randomize , open-label , multicenter study compare EFV+FTC+TDF ( administer individual component drug ) versus CBV ( lamivudine/zidovudine ) + EFV ass efficacy safety treatment ART-Naive , HIV-1 infect participant . The regimen CBV ( administer twice daily ) + EFV ( administer daily ) serve active control treatment compare regimen EFV+FTC+TDF ; component drug EFV+FTC+TDF regimen administer daily . Week 48 Week 96 : The study extend continued evaluate efficacy safety two regimen total treatment duration 96 week . The regimen EFV+FTC+TDF continue dosed component drug ( EFV + FTC + TDF ) , daily , without regard meal . The regimen CBV+EFV dose 2 pill ( CBV , twice daily morning without regard meal ) + EFV ( daily , without regard meal ) . Week 96 Week 144 : A study extension change 3-pill EFV+FTC+TDF regimen 2-pill regimen EFV + Truvada ( [ TVD ] : fixed-dose combination pill contain FTC/TDF ) , daily without regard meal , continue evaluate efficacy safety two regimens 48 week total study treatment duration 144 week . The regimen CBV+EFV continue dosed 2 pill ( CBV , twice daily morning without regard meal ) + EFV ( daily , without regard meal ) . Week 144 end study ( Week 240 ) : A final study extension provide study participant treatment regimens option switch respective treatment 1-pill regimen 96 week total study duration 240 week ( 5 year ) assess efficacy safety ART regimen simplification . At site France , study extend 48 week ( Year 6 ) ATR become commercially available ( whichever happen first ) ; ATR become commercially available France participant require complete full 288 week study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Participants must meet inclusion criterion within 28 day prior randomization unless specify otherwise include : Plasma HIV1 RNA level great 10,000 c/mL use Roche Amplicor HIV1 Monitor Test Version 1.5 Standard Adequate renal function : Calculated creatinine clearance great equal 50 mL/min accord CockcroftGault Formula . Hepatic transaminase ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) 3 x upper limit normal ( ULN ) . Total bilirubin less equal 1.5 mg/dL . Adequate hematologic function ( absolute neutrophil count great equal 1,000/mm^3 ; platelet great equal 50,000/mm^3 ; hemoglobin great equal 8.0 g/dL ) . Serum amylase less equal 1.5 x ULN . Serum phosphorus great equal 2.2 mg/dL . Willingness use effective contraception male female study treatment 30 day follow study drug completion . Life expectancy great equal 1 year The ability understand sign write informed consent form obtain prior initiation study procedure . Participants eligible entry study follow met : Prior treatment nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , nucleoside reverse transcriptase inhibitor ( NRTI ) , protease inhibitor ( PI ) . A new AIDSdefining condition diagnose ( exception CD4 criterion ) within 30 day baseline . Receiving ongoing therapy following : nephrotoxic agent , probenecid , systemic chemotherapeutic agent , systemic corticosteroid , interleukin2 , drug interact efavirenz . Administration medication must discontinue least 30 day prior baseline visit duration study . Pregnant lactate participant . Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Participants biopsyconfirmed KS eligible must receive systemic therapy KS within 30 day baseline anticipate start systemic therapy study . Prior history renal bone disease . Any clinical condition prior therapy would make participant unsuitable study unable comply dose requirement opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>